Healthcare ETF (XLV) Hits a New 52-Week High

For investors looking for momentum, Health Care Select Sector SPDR Fund XLV is probably a suitable pick. The fund just hit a 52-week high and is up 36.4% from its 52-week low of $100.31/share.

Let’s take a look at the fund and its near-term outlook to gain an insight into where it might be headed in future:

XLV in Focus

The fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the Health Care Select Sector Index. It has AUM of $32.41 billion and charges 12 basis points in annual fees.

Why the Move?

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investing opportunities in the healthcare sector. Moreover, the space has been gaining increasing attention lately, largely due to the resurgence in COVID-19 infections due to the highly-contagious delta variant. This has made investors jittery, compelling them to shift toward defensive investments. It is making funds like XLV an attractive investment option.

More Gains Ahead?

The fund has a Zacks ETF Rank #1 (Strong Buy). It seems like XLV will remain strong, with a positive weighted alpha of 31.56, which gives cues of further rally.

Zacks’ Top Picks to Cash in on Artificial Intelligence

This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.

See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>

Click to get this free report

Health Care Select Sector SPDR ETF (XLV): ETF Research Reports

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Technology Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More